ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,443.72
0.28%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,438.125
0.77%
Brent Oil
84.02
0.51%
Bitcoin
66,841.31
1.03%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. SciSparc Ltd (SPRC)

  7. SciSparc Ltd (SPRC) News

SciSparc (SPRC)

SciSparc Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRC
DateTimeSourceHeadlineSymbolCompany
11/04/202413:15GlobeNewswire Inc.SciSparc to Acquire AutoMaxNASDAQ:SPRCSciSparc Ltd
21/03/202412:58GlobeNewswire Inc.SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchNASDAQ:SPRCSciSparc Ltd
18/03/202411:29GlobeNewswire Inc.SciSparc Granted Another Patent, Strengthening its Core Technology in CanadaNASDAQ:SPRCSciSparc Ltd
14/03/202412:49GlobeNewswire Inc.SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical TrialNASDAQ:SPRCSciSparc Ltd
12/03/202412:14GlobeNewswire Inc.SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule StructureNASDAQ:SPRCSciSparc Ltd
08/03/202414:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
08/03/202412:11GlobeNewswire Inc.SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
07/03/202412:49GlobeNewswire Inc.SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in EuropeNASDAQ:SPRCSciSparc Ltd
07/03/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SPRCSciSparc Ltd
06/03/202421:41GlobeNewswire Inc.SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyNASDAQ:SPRCSciSparc Ltd
29/02/202414:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
29/02/202413:35GlobeNewswire Inc.SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of DosingNASDAQ:SPRCSciSparc Ltd
27/02/202421:15Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:SPRCSciSparc Ltd
27/02/202413:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
27/02/202412:58GlobeNewswire Inc.SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
27/02/202412:58GlobeNewswire Inc.Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
20/02/202421:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
20/02/202412:14GlobeNewswire Inc.SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
20/02/202412:14GlobeNewswire Inc.Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
12/02/202421:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
29/01/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
29/01/202412:18GlobeNewswire Inc.SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
25/01/202414:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
24/01/202412:42GlobeNewswire Inc.SciSparc Ltd. Announces $20 Million Standby Equity Purchase AgreementNASDAQ:SPRCSciSparc Ltd
22/01/202411:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
19/01/202414:28GlobeNewswire Inc.SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 millionNASDAQ:SPRCSciSparc Ltd
04/01/202412:18GlobeNewswire Inc.SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based TreatmentsNASDAQ:SPRCSciSparc Ltd
04/01/202412:18GlobeNewswire Inc.Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based TreatmentsNASDAQ:SPRCSciSparc Ltd
13/12/202313:18GlobeNewswire Inc.SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery PlatformNASDAQ:SPRCSciSparc Ltd
08/12/202313:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
 Showing the most relevant articles for your search:NASDAQ:SPRC

Your Recent History

LSE
KEFI
Kefi Gold And Copper
LSE
ENET
Ethernity Networks
LSE
SOLG
Solgold
LSE
NEXN
Nexxen
LSE
GGP
Greatland Gold
LSE
VAST
Vast Resources
LSE
SYME
Supply@me Capital
LSE
AAZ
Anglo Asian Mining
LSE
POS
Plexus
LSE
ITX
Itaconix
LSE
GKP
Gulf Keystone Petroleum
LSE
TERN
Tern
LSE
INDI
Indus Gas
LSE
GOLD
LSE
AGL
Angle
LSE
PANR
Pantheon Resources
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved